** Shares of Solid Biosciences SLDB.O rises 51.9% to $6.12
** Co says its experimental gene therapy for a rare muscle wasting disorder was well-tolerated in 6 participants dosed in an early-stage study
** Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, which interferes with the production of proteins needed to form healthy muscles
** Says no serious adverse events were observed
** Also says that some patients showed significant improvements in multiple muscle health biomarkers
** Separately, co's 35.7 mln stock offering priced at $4.03 each, which was the last closing price of its shares
** SLDB has fallen ~56% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。